Galderma’s Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines

Contributed by: Business Wire

Logo

Tags

Biotechnology

Health

Clinical Trials

Other Health

Aesthetics

More Like This

Galderma’s Relfydess™ (RelabotulinumtoxinA) Receives Positive Decision for Use in Europe

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics

IMCAS 2025: New Galderma Phase IIIb Data Reinforce Rapid Onset and Long-lasting Aesthetic Improvement with RelabotulinumtoxinA (Relfydess™)

ASDS 2024: New Phase III READY-4 Data Demonstrate Long-Term Safety and Efficacy of Galderma’s RelabotulinumtoxinA (Relfydess™)

Galderma Announces U.S. FDA Acceptance of RelabotulinumtoxinA Biologics License Application Resubmission

IMCAS 2025: Galderma’s Broad Presence and New Data on Recently Launched Products Restylane® SHAYPE™ and Relfydess® Reaffirm Its Category Leadership

Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States

TOXINS 2024: Galderma’s Phase III RelabotulinumtoxinA Results Demonstrate Positive Efficacy and Long Duration of Effect When Treating Frown Lines and Crow’s Feet Simultaneously